# Daiichi Sankyo

> Daiichi Sankyo is a VC fund in Parsippany backing Medical and Health Care. See 2 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Parsippany, United States
- Total investments: 2
- Last investment: Jul 2018
- Lead investor: 50%
- Last updated: Aug 2026
- X (Twitter): https://www.twitter.com/daiichisankyo
- Website: http://www.daiichisankyo.com

Daiichi Sankyo is a VC fund in Parsippany focused on Medical and Health Care. Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxoninfor bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.

## Contacts

5 contacts available for Daiichi Sankyo. Shizune tracks 6 team members at Daiichi Sankyo. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/daiichi-sankyo?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |
| Medical Device | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Funding Round | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Glenn Gormley | Senior Executive Officer & Global Head of Research & Development | 0 | https://shizune.co/investors/profile/glenn-gormley |
| Hiroshi Nakagawa | Formulation Technology Director | 0 | https://shizune.co/investors/profile/hiroshi-nakagawa |
| John Vieira | Executive Director, Global Brand Strategy | 0 | https://shizune.co/investors/profile/john-vieira |
| Robin Edwards | Vice President and Global Head, Translational Sciences & Biomarkers | 0 | https://shizune.co/investors/profile/robin-edwards |
| Rohit Heryani | Sr. Manager, Multi-channel Marketing | 0 | https://shizune.co/investors/profile/rohit-heryani |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cuorips | CUORiPS is a company developing new medical care based on world's cutting-edge technology originated in Japan. | $141.7M |  | Jul 20, 2018 | https://www.cuorips.co.jp/en/technology/ |
| SymBio Pharmaceuticals | SymBio Pharmaceuticals Limited operates as a biopharmaceutical company. It offers Symbenda medicine for treating low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia in Singapore. The company was founded in 2005 and is headquartered in Tokyo, Japan. |  | Series A | Oct 18, 2005 | http://www.symbiopharma.com |

2 of 2 investments shown.

## Co-investors
- [Kyoto University Innovation Capital](https://shizune.co/investors/profile/kyoto-university-innovation-capital) — VC Fund, 1 deal together
- [SBI Group](https://shizune.co/investors/profile/sbi-group) — VC Fund, 1 deal together
- [Terumo Corporation](https://shizune.co/investors/profile/terumo-corporation) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Japan](https://shizune.co/investors/biotechnology-investors-japan)
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)

## FAQ

### What does Daiichi Sankyo invest in?

Daiichi Sankyo invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Daiichi Sankyo?

Public channels for Daiichi Sankyo include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Daiichi Sankyo?

The team at Daiichi Sankyo includes Glenn Gormley (Senior Executive Officer & Global Head of Research & Development), Hiroshi Nakagawa (Formulation Technology Director) and John Vieira (Executive Director, Global Brand Strategy), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co